<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="correction"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Orphanet J Rare Dis</journal-id><journal-id journal-id-type="iso-abbrev">Orphanet J Rare Dis</journal-id><journal-title-group><journal-title>Orphanet Journal of Rare Diseases</journal-title></journal-title-group><issn pub-type="epub">1750-1172</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27387831</article-id><article-id pub-id-type="pmc">4937550</article-id><article-id pub-id-type="publisher-id">463</article-id><article-id pub-id-type="doi">10.1186/s13023-016-0463-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Erratum</subject></subj-group></article-categories><title-group><article-title>Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Attarian</surname><given-names>Shahram</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Vallat</surname><given-names>Jean-Michel</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Magy</surname><given-names>Laurent</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Funalot</surname><given-names>Beno&#x000ee;t</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Gonnaud</surname><given-names>Pierre-Marie</given-names></name><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Lacour</surname><given-names>Arnaud</given-names></name><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>P&#x000e9;r&#x000e9;on</surname><given-names>Yann</given-names></name><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Dubourg</surname><given-names>Odile</given-names></name><xref ref-type="aff" rid="Aff7"/></contrib><contrib contrib-type="author"><name><surname>Pouget</surname><given-names>Jean</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Micallef</surname><given-names>Jo&#x000eb;lle</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Franques</surname><given-names>J&#x000e9;r&#x000f4;me</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Lefebvre</surname><given-names>Marie-No&#x000eb;lle</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Ghorab</surname><given-names>Karima</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Al-Moussawi</surname><given-names>Mahmoud</given-names></name><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Tiffreau</surname><given-names>Vincent</given-names></name><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Preudhomme</surname><given-names>Marguerite</given-names></name><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Magot</surname><given-names>Armelle</given-names></name><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Leclair-Visonneau</surname><given-names>Laur&#x000e8;ne</given-names></name><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Stojkovic</surname><given-names>Tanya</given-names></name><xref ref-type="aff" rid="Aff7"/></contrib><contrib contrib-type="author"><name><surname>Bossi</surname><given-names>Laura</given-names></name><xref ref-type="aff" rid="Aff8"/></contrib><contrib contrib-type="author"><name><surname>Lehert</surname><given-names>Philippe</given-names></name><xref ref-type="aff" rid="Aff9"/><xref ref-type="aff" rid="Aff10"/></contrib><contrib contrib-type="author"><name><surname>Gilbert</surname><given-names>Walter</given-names></name><xref ref-type="aff" rid="Aff11"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Bertrand</surname><given-names>Viviane</given-names></name><xref ref-type="aff" rid="Aff12"/></contrib><contrib contrib-type="author"><name><surname>Mandel</surname><given-names>Jonas</given-names></name><xref ref-type="aff" rid="Aff12"/></contrib><contrib contrib-type="author"><name><surname>Milet</surname><given-names>Aude</given-names></name><xref ref-type="aff" rid="Aff12"/></contrib><contrib contrib-type="author"><name><surname>Hajj</surname><given-names>Rodolphe</given-names></name><xref ref-type="aff" rid="Aff12"/></contrib><contrib contrib-type="author"><name><surname>Boudiaf</surname><given-names>Lamia</given-names></name><xref ref-type="aff" rid="Aff12"/></contrib><contrib contrib-type="author"><name><surname>Scart-Gr&#x000e8;s</surname><given-names>Catherine</given-names></name><xref ref-type="aff" rid="Aff12"/></contrib><contrib contrib-type="author"><name><surname>Nabirotchkin</surname><given-names>Serguei</given-names></name><xref ref-type="aff" rid="Aff12"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Guedj</surname><given-names>Mickael</given-names></name><xref ref-type="aff" rid="Aff12"/></contrib><contrib contrib-type="author"><name><surname>Chumakov</surname><given-names>Ilya</given-names></name><xref ref-type="aff" rid="Aff12"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Cohen</surname><given-names>Daniel</given-names></name><address><email>daniel.cohen@pharnext.com</email></address><xref ref-type="aff" rid="Aff12"/></contrib><aff id="Aff1"><label/>Centre de r&#x000e9;f&#x000e9;rence des maladies neuromusculaires et de la SLA, P&#x000f4;le des neurosciences Cliniques, AP-HM et Aix Marseille Universit&#x000e9;, Marseille, France </aff><aff id="Aff2"><label/>CIC-Centre de Pharmacologie Clinique et D&#x02019;Evaluations Therapeutiques, AP-HM et Aix Marseille Universit&#x000e9;, Marseille, France </aff><aff id="Aff3"><label/>CHU de Limoges - H&#x000f4;pital Dupuytren, 2 Avenue Martin Luther King, 87042 Limoges, France </aff><aff id="Aff4"><label/>CHU Lyon Sud, 165 Chemin du Grand Revoyet, 69495 Lyon, France </aff><aff id="Aff5"><label/>CHRU de Lille - H&#x000f4;pital Roger Salengro, rue Emile Laine, 59037 Lille, France </aff><aff id="Aff6"><label/>CHU de Nantes - H&#x000f4;tel Dieu, 1 place Alexis Ricordeau, 44093 Nantes, France </aff><aff id="Aff7"><label/>CHU de Paris - Groupe Hospitalier Piti&#x000e9;-Salp&#x000e9;tri&#x000e8;re, 47-83 boulevard de l&#x02019;H&#x000f4;pital, 75013 Paris, France </aff><aff id="Aff8"><label/>Admissions, 75017 Paris, France </aff><aff id="Aff9"><label/>Faculty of Medicine, The University of Melbourne, Grattan St, Melbourne, VIC 3010 Australia </aff><aff id="Aff10"><label/>Faculty of Economics, UCL Mons, Louvain, Belgium </aff><aff id="Aff11"><label/>Carl M. Loeb University Professor Emeritus, Harvard University, Cambridge, MA 02138 USA </aff><aff id="Aff12"><label/>Pharnext, 11, rue des Peupliers, 92130 Issy-Les-Moulineaux, Paris, France </aff></contrib-group><pub-date pub-type="epub"><day>7</day><month>7</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>7</day><month>7</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>11</volume><elocation-id>92</elocation-id><history><date date-type="received"><day>16</day><month>5</month><year>2016</year></date><date date-type="accepted"><day>16</day><month>5</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><related-article related-article-type="corrected-article" id="d30e69" ext-link-type="doi" xlink:href="10.1186/s13023-014-0199-0"/><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Unfortunately, the original version of this article [<xref ref-type="bibr" rid="CR1">1</xref>] contained an error due to a typographical error in the computer code used. This meant the percentage improvement over baseline of the endpoints CMTNS, ONLS, 9HPT and DML was slightly increased. Therefore some of the values in Tables&#x000a0;<xref rid="Tab1" ref-type="table">3</xref>, <xref rid="Tab2" ref-type="table">4</xref>, Additional file <xref rid="MOESM1" ref-type="media">4</xref>: Table S4 and Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">4</xref> are incorrect.<table-wrap id="Tab1"><label>Table 3</label><caption><p>Response to PXT3003 on efficacy outcomes in treatment groups, with comparisons of active doses versus Placebo (Full Analysis Set, <italic>n</italic>&#x02009;=&#x02009;80)</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="4">Mean % of improvement</th><th colspan="2">PXT3003 LD versus Placebo</th><th colspan="2">PXT3003 ID versus Placebo</th><th colspan="2">PXT3003 HD versus Placebo</th><th colspan="2">Dose-effect</th></tr><tr><th rowspan="2"/><th>Placebo</th><th>PXT3003 LD</th><th>PXT3003 ID</th><th>PXT3003 HD</th><th rowspan="2">Estimate</th><th rowspan="2">
<italic>P</italic>-value</th><th rowspan="2">Estimate</th><th rowspan="2">
<italic>P</italic>-value</th><th rowspan="2">Estimate</th><th rowspan="2">
<italic>P</italic>-value</th><th rowspan="2">Correlation</th><th rowspan="2">
<italic>P</italic>-value</th></tr><tr><th>(<italic>n</italic>&#x02009;=&#x02009;19)</th><th>(<italic>n</italic>&#x02009;=&#x02009;21)</th><th>(<italic>n</italic>&#x02009;=&#x02009;21)</th><th>(<italic>n</italic>&#x02009;=&#x02009;19)</th></tr></thead><tbody><tr><td>CMTNS</td><td>&#x02212;0.25 (17.3)</td><td>&#x02212;3.8 (20.4)</td><td>&#x02212;5.8 (17.7)</td><td>
<bold>5.2 (12.5)</bold>
</td><td>&#x02212;2.6 (&#x02212;11.9;7.6)</td><td>0.67</td><td>&#x02212;3.1 (&#x02212;11.0;5.4)</td><td>0.74</td><td>5.5 (&#x02212;3.4;15.2)</td><td>0.16</td><td>0.54</td><td>0.30</td></tr><tr><td>ONLS</td><td>&#x02212;11.8 (33.7)</td><td>&#x02212;12.7 (31.7)</td><td>1.2 (16.7)</td><td>
<bold>6.8 (18.2)</bold>
</td><td>&#x02212;3.9 (&#x02212;14.2;7.6)</td><td>0.72</td><td>6.9 (&#x02212;3.8;18.8)</td><td>0.15</td><td>14.4 (0.55;30.2)</td><td>0.043*</td><td>0.28</td><td>0.006*</td></tr><tr><td>6MWT (m)</td><td>9.0 (8.3)</td><td>6.2 (8.3)</td><td>6.4 (9.4)</td><td>
<bold>9.9 (6.9)</bold>
</td><td>&#x02212;2.4 (&#x02212;6.2;1.5)</td><td>0.85</td><td>&#x02212;2.4 (&#x02212;6.6;2.0)</td><td>0.82</td><td>0.7 (&#x02212;3.2;4.7)</td><td>0.38</td><td>0.11</td><td>0.16</td></tr><tr><td>9HPT (s)</td><td>3.6 (10.9)</td><td>&#x02212;2.5 (12)</td><td>4.4 (9.5)</td><td>
<bold>6.1 (10.6)</bold>
</td><td>&#x02212;4.6 (&#x02212;10.3;1.5)</td><td>0.89</td><td>&#x02212;0.2 (&#x02212;5.3;5.2)</td><td>0.52</td><td>0.3 (&#x02212;5.7;6.6)</td><td>0.47</td><td>0.15</td><td>0.092</td></tr><tr><td>Ankle Dorsiflexion (Nm)</td><td>20.2 (88.4)</td><td>&#x02212;3.6 (43.0)</td><td>
<bold>81.5 (369.6)</bold>
</td><td>20.4 (64.1)</td><td>&#x02212;4.0 (&#x02212;21.7;17.8)</td><td>0.63</td><td>11.4 (&#x02212;15.4;46.8)</td><td>0.26</td><td>8.2 (&#x02212;13.8;35.9)</td><td>0.28</td><td>0.11</td><td>0.16</td></tr><tr><td>Grip (kg)</td><td>9.9 (24.2)</td><td>1.3 (15.6)</td><td>4.7 (12.5)</td><td>
<bold>11.7 (18.1)</bold>
</td><td>&#x02212;7.1 (&#x02212;15.6;2.1)</td><td>0.90</td><td>&#x02212;3.6 (&#x02212;11.8;5.4)</td><td>0.75</td><td>1.6 (&#x02212;7.7;11.9)</td><td>0.39</td><td>0.12</td><td>0.15</td></tr><tr><td>CMAP (milliV)</td><td>34.4 (62.0)</td><td>1.4 (38.7)</td><td>22.9 (62.6)</td><td>
<bold>64.2 (208.5)</bold>
</td><td>&#x02212;25.1 (&#x02212;44.8;1.5)</td><td>0.94</td><td>&#x02212;9.2 (&#x02212;27.3;13.5)</td><td>0.77</td><td>&#x02212;5.1 (&#x02212;27.1;23.6)</td><td>0.63</td><td>&#x02212;0.001</td><td>0.50</td></tr><tr><td>MCV (m/s)</td><td>3.7 (8.5)</td><td>3.0 (11.5)</td><td>5.7 (12.3)</td><td>
<bold>9.0 (17.6)</bold>
</td><td>&#x02212;1.0 (&#x02212;6.5;4.9)</td><td>0.61</td><td>0.5 (&#x02212;4.8;6.2)</td><td>0.44</td><td>2.8 (&#x02212;3.4;9.4)</td><td>0.23</td><td>0.11</td><td>0.18</td></tr><tr><td>DML (ms)</td><td>&#x02212;0.33 (8.7)</td><td>0.33 (16.1)</td><td>
<bold>8.3 (18.1)</bold>
</td><td>5 (15.2)</td><td>3.4 (&#x02212;4.3;11.7)</td><td>0.24</td><td>13.8 (4.2;24.3)</td><td>0.009*</td><td>8.0 (0.59;16.0)</td><td>0.038*</td><td>0.21</td><td>0.035*</td></tr><tr><td>SNAP (microV)</td><td>12.4 (121.7)</td><td>11.5 (88.2)</td><td>
<bold>23.3 (128.4)</bold>
</td><td>5.2 (69.0)</td><td>&#x02212;1.2 (&#x02212;42.9;71.0)</td><td>0.52</td><td>8.7 (&#x02212;31.2;71.6)</td><td>0.38</td><td>13.9 (&#x02212;24.1;71.0)</td><td>0.29</td><td>0.09</td><td>0.30</td></tr><tr><td>SCV (m/s)</td><td>3.4 (11.0)</td><td>5.3 (11.2)</td><td>29.5 (63.4)</td><td>
<bold>30.5 (10.0)</bold>
</td><td>1.5 (&#x02212;5.8;9.4)</td><td>0.36</td><td>17.5 (&#x02212;5.5;46.2)</td><td>0.11&#x02020;</td><td>26.6 (15.5;38.8)</td><td>0.00037*</td><td>0.42</td><td>0.01*</td></tr></tbody></table><table-wrap-foot><p>Data are mean % (s.d.) of improvement for each treatment group. Differences between treatment groups were assessed by Analysis of Covariance (ANCOVA) on log-transformed values by adjusting for baseline values. Estimates were provided as mean percentage change over baseline (90&#x000a0;% CI). Dose-effect was tested through Spearman&#x02019;s rank correlation. <italic>P</italic>-values are one-tailed. *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05; Shading&#x02009;=&#x02009;best improvement within dosages. <italic>CMTNS</italic> Charcot-Marie-Tooth Neuropathy Score, <italic>ONLS</italic> Overall Neuropathy Limitations Scale, <italic>6MWT</italic> 6-Minute Walk Test, <italic>9HPT</italic> 9-Hole Peg Test, <italic>CMAP</italic> Amplitudes of Compound Muscle Action Potentials, <italic>MCV</italic> Motor Conduction Velocity, <italic>DML</italic> Distal Motor Latency, <italic>SNAP</italic> Amplitudes of Sensory Nerve Action Potentials, <italic>SCV</italic> Sensitive Conduction Velocity</p></table-wrap-foot></table-wrap><table-wrap id="Tab2"><label>Table 4</label><caption><p>Response to PXT3003 on efficacy outcomes in HD and in PLI, with comparisons of HD versus PLI (Full Analysis Set, <italic>n</italic>&#x02009;=&#x02009;80)</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="2">Mean % of improvement</th><th colspan="2">PXT3003 HD versus PLI</th></tr><tr><th rowspan="2"/><th>PLI</th><th>PXT3003 HD</th><th rowspan="2">Estimate</th><th rowspan="2">
<italic>P</italic>-value</th></tr><tr><th>(<italic>n</italic>&#x02009;=&#x02009;61)</th><th>(<italic>n</italic>&#x02009;=&#x02009;19)</th></tr></thead><tbody><tr><td>CMTNS</td><td>&#x02212;3.4 (18.4)</td><td>
<bold>5.2 (12.5)</bold>
</td><td>8.0 (0.4;16.2)</td><td>0.042*</td></tr><tr><td>ONLS</td><td>&#x02212;7.7 (28.5)</td><td>
<bold>6.8 (18.2)</bold>
</td><td>12.1 (2.0;23.2)</td><td>0.024*</td></tr><tr><td>6MWT (m)</td><td>7.1 (8.6)</td><td>
<bold>9.9 (6.9)</bold>
</td><td>2.6 (&#x02212;0.73;6.1)</td><td>0.099</td></tr><tr><td>9HPT (s)</td><td>1.8 (11.1)</td><td>
<bold>6.1 (10.6)</bold>
</td><td>1.2 (&#x02212;3.4;6.0)</td><td>0.33</td></tr><tr><td>Ankle Dorsiflexion (Nm)</td><td>
<bold>33.1 (223.2)</bold>
</td><td>20.4 (64.1)</td><td>5.5 (&#x02212;12.8;27.7)</td><td>0.32</td></tr><tr><td>Grip (kg)</td><td>5.1 (17.9)</td><td>
<bold>11.7 (18.1)</bold>
</td><td>6.0 (&#x02212;1.2;13.7)</td><td>0.088</td></tr><tr><td>CMAP (milliV)</td><td>19.6 (56.5)</td><td>
<bold>64.2 (208.5)</bold>
</td><td>6.6 (&#x02212;15.8;35.1)</td><td>0.33</td></tr><tr><td>MCV (m/s)</td><td>4.2 (10.9)</td><td>
<bold>9.0 (17.6)</bold>
</td><td>2.5 (&#x02212;2.4;7.7)</td><td>0.21</td></tr><tr><td>DML (ms)</td><td>3 (15.3)</td><td>
<bold>5 (15.2)</bold>
</td><td>2.2 (&#x02212;5.1;10.0)</td><td>0.31</td></tr><tr><td>SNAP (microV)</td><td>
<bold>15.9 (110.2)</bold>
</td><td>5.2 (69.0)</td><td>12.0 (&#x02212;23.9;64.9)</td><td>0.31</td></tr><tr><td>SCV (m/s)</td><td>12.7 (38.0)</td><td>
<bold>30.5 (10.0)</bold>
</td><td>20.1 (2.4;40.8)</td><td>0.030*</td></tr></tbody></table><table-wrap-foot><p>Data are mean % (s.d.) of improvement for HD and for PLI after 12&#x000a0;months. Differences between treatment groups were assessed by Analysis of Covariance (ANCOVA) on log-transformed values by adjusting for baseline values. Estimates were provided as mean percentage change over baseline (90&#x000a0;% CI). <italic>P</italic>-values are one-tailed. *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05; Shading&#x02009;=&#x02009;best improvement within groups. <italic>CMTNS</italic> Charcot-Marie-Tooth Neuropathy Score, <italic>ONLS</italic> Overall Neuropathy Limitations Scale, <italic>6MWT</italic> 6-Minute Walk Test, <italic>9HPT</italic> 9-Hole Peg Test, <italic>CMAP</italic> Amplitudes of Compound Muscle Action Potentials, <italic>MCV</italic> Motor Conduction Velocity, <italic>DML</italic> Distal Motor Latency, <italic>SNAP</italic> Amplitudes of Sensory Nerve Action Potentials, <italic>SCV</italic> Sensitive Conduction Velocity</p></table-wrap-foot></table-wrap><fig id="Fig1"><label>Fig. 4</label><caption><p>Response to PXT3003 on clinical scales (Full Analysis Set, <italic>n</italic>&#x02009;=&#x02009;80). Mean % (s.e.m.) of improvement from baseline per group at 12&#x000a0;months for CMTNS (<bold>a</bold>) and ONLS (<bold>b</bold>). Sample sizes: Placebo (<italic>n</italic>&#x02009;=&#x02009;19), LD (<italic>n</italic>&#x02009;=&#x02009;21), ID (<italic>n</italic>&#x02009;=&#x02009;21), HD (<italic>n</italic>&#x02009;=&#x02009;19)</p></caption><graphic xlink:href="13023_2016_463_Fig1_HTML" id="MO3"/></fig></p><p>However this error has no bearing on statistical outcome of the study, the conclusions or text of the manuscript. Correct versions of Tables&#x000a0;<xref rid="Tab1" ref-type="table">3</xref>, <xref rid="Tab2" ref-type="table">4</xref> and Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">4</xref> can be seen below and Additional file <xref rid="MOESM1" ref-type="media">4</xref> accessed using the link below.</p></body><back><app-group><app id="App1"><sec id="Sec1"><title>Additional file</title><p><media position="anchor" xlink:href="13023_2016_463_MOESM1_ESM.doc" id="MOESM1"><label>Additional file 4: Table S4.</label><caption><p>Response to PXT3003 on efficacy outcomes (Full Analysis Set, <italic>n</italic>&#x02009;=&#x02009;80). Data are mean (s.d.) baseline and final values, and % (s.d.) of improvement for each treatment group and PLI. Differences between treatment groups were assessed by Analysis of Covariance (Ancova) on log-transformed values by adjusting for baseline values. Estimates were provided as mean percentage change over baseline (90&#x000a0;% CI). Dose-effect was tested through Spearman&#x02019;s rank correlation. <italic>P</italic>-values are one-tailed. CMTNS&#x02009;=&#x02009;Charcot-Marie-Tooth Neuropathy Score; ONLS&#x02009;=&#x02009;Overall Neuropathy Limitations Scale; 6MWT&#x02009;=&#x02009;6-Minute Walk Test; 9HPT&#x02009;=&#x02009;9-Hole Peg Test; CMAP&#x02009;=&#x02009;Amplitudes of Compound Muscle Action Potentials; MCV&#x02009;=&#x02009;Motor Conduction Velocity; DML&#x02009;=&#x02009;Distal Motor Latency; SNAP&#x02009;=&#x02009;Amplitudes of Sensory Nerve Action Potentials; SCV&#x02009;=&#x02009;Sensitive Conduction Velocity; VAS&#x02009;=&#x02009;Visual Analog Scale; CGI&#x02009;=&#x02009;Clinical Global Impression. (DOC 168&#x000a0;kb)</p></caption></media></p></sec></app></app-group><fn-group><fn><p>The online version of the original article can be found under doi:10.1186/s13023-014-0199-0.</p></fn></fn-group><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Attarian</surname><given-names>S</given-names></name><name><surname>Vallat</surname><given-names>JM</given-names></name><name><surname>Magy</surname><given-names>L</given-names></name><name><surname>Funalot</surname><given-names>B</given-names></name><name><surname>Gonnaud</surname><given-names>PM</given-names></name><name><surname>Lacour</surname><given-names>A</given-names></name><name><surname>P&#x000e9;r&#x000e9;on</surname><given-names>Y</given-names></name><name><surname>Dubourg</surname><given-names>O</given-names></name><name><surname>Pouget</surname><given-names>J</given-names></name><name><surname>Micallef</surname><given-names>J</given-names></name><name><surname>Franques</surname><given-names>J</given-names></name><name><surname>Lefebvre</surname><given-names>MN</given-names></name><name><surname>Ghorab</surname><given-names>K</given-names></name><name><surname>Al-Moussawi</surname><given-names>M</given-names></name><name><surname>Tiffreau</surname><given-names>V</given-names></name><name><surname>Preudhomme</surname><given-names>M</given-names></name><name><surname>Magot</surname><given-names>A</given-names></name><name><surname>Leclair-Visonneau</surname><given-names>L</given-names></name><name><surname>Stojkovic</surname><given-names>T</given-names></name><name><surname>Bossi</surname><given-names>L</given-names></name><name><surname>Lehert</surname><given-names>P</given-names></name><name><surname>Gilbert</surname><given-names>W</given-names></name><name><surname>Bertrand</surname><given-names>V</given-names></name><name><surname>Mandel</surname><given-names>J</given-names></name><name><surname>Milet</surname><given-names>A</given-names></name><name><surname>Hajj</surname><given-names>R</given-names></name><name><surname>Boudiaf</surname><given-names>L</given-names></name><name><surname>Scart-Gr&#x000e8;s</surname><given-names>C</given-names></name><name><surname>Nabirotchkin</surname><given-names>S</given-names></name><name><surname>Guedj</surname><given-names>M</given-names></name><name><surname>Chumakov</surname><given-names>I</given-names></name><name><surname>Cohen</surname><given-names>D</given-names></name></person-group><article-title>An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A</article-title><source>Orphanet J Rare Dis.</source><year>2014</year><volume>9</volume><fpage>199</fpage><pub-id pub-id-type="doi">10.1186/s13023-014-0199-0</pub-id><pub-id pub-id-type="pmid">25519680</pub-id></element-citation></ref></ref-list></back></article>